(cm^{-1}) at 1625 cm ± 2; and a solid state NMR spectrum comprising a ^{13}C chemical shift (ppm) at 171.5 ± 0.2.

10. The crystalline form of any one of claims 1-9, wherein said form is non-hygroscopic and anhydrous.

11. The crystalline form of any one of claims 1-10, wherein said form is substantially pure.

12. A pharmaceutical composition comprising the crystalline form of any one of claims 1-11.

~~13. A method of treating transthyretin amyloid disease in a mammal, the method comprising administering to the mammal a therapeutically effective amount of the crystalline form of any one of claims 1-12.~~